NextCure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by NextCure, Inc. (NXTC) on September 24, 2021, covering events occurring on September 21, 2021. The Company is a Delaware corporation with principal executive offices in Beltsville, Maryland, and its common stock trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On September 21, 2021, Dr. Stella Xu notified the Company of her resignation from the Board of Directors, effective September 30, 2021. The Company stated that the resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the disclosure of the director's departure.
Investor Verification Checklist
- Verify the effective date of Dr. Stella Xu's resignation (September 30, 2021).
- Confirm whether the Board has appointed a replacement director to fill the vacancy.
- Review subsequent filings for any impact on the Company's strategic direction or governance structure.